Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 5Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Kidney Neoplasms 1Glioma 1Ependymoma 1Carcinoma, Merkel Cell 1

Interventions

enzalutamide 5olaparib 4Abiraterone Acetate 4radium Ra 223 dichloride 2poly ICLC 1fluciclovine F-18 1darolutamide 1bempegaldesleukin 1avelumab 1abiraterone 1Radiosurgery 1Prednisone 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Castration-resistant Prostate Cancer × bempegaldesleukin × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡